Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View [Seeking Alpha]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Seeking Alpha
The company deployed $2.6 billion into 9 new royalties and repurchased $1.2 billion in shares, reflecting disciplined capital allocation and shareholder focus. Even factoring in patent expiries and a more conservative growth outlook, valuation remains attractive, supported by sector momentum and sustained capital returns. Drs Producoes/E+ via Getty Images Following the Q4 and full-year 2025 results, we revisit Royalty Pharma plc (NASDAQ: RPRX ) with a constructive stance. Execution remains solid, and we continue to view the stock as an attractive entry point, supported by resilient figures, recent This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of RPRX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c+)" rating to a "buy (b-)" rating.MarketBeat
- Royalty Pharma (NASDAQ:RPRX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions [Seeking Alpha]Seeking Alpha
RPRX
Sec Filings
- 2/13/26 - Form SCHEDULE
- 2/13/26 - Form 4
- 2/13/26 - Form 4
- RPRX's page on the SEC website